In this interview at ESMO 2018, Marc Peeters talks to touchONCOLOGY about colorectal cancer tumour location and biomarkers. He explains that left-sided cancers have a better prognosis and suggests some possible reasons for this. Dr Peeters also discusses how the use of biomarkers has developed in the last 10 years and how treatment and prognosis can be guided using these biomarkers. This development is largely down to progress in technology, such as easier access to next generation sequencing, and the advent of liquid biopsies. Unfortunately, there are certain types of colorectal cancers with a poor prognosis, such as RAS- and BRAF-mutated tumours. There is still a need for biologics that can be added to standard chemotherapy in patients with these tumours.
1. What has been the most important recent therapeutic breakthrough in metastatic colorectal cancer? (0:11)
2. What is the prognostic significance of tumour location in colorectal cancer? (0:59)
3. What progress has been made in understanding the prognostic significance of molecular biomarkers in colorectal cancer? (1:45)
4. What are the most important unmet needs in colorectal cancer? (3:09)
5. What do you expect to be the highlights of this year’s ESMO congress? (4:21)
Speaker disclosures: Marc Peeters has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Gastrointestinal Oncology
Jean-Luc Van Laethem, ASCO GI 2021: Pembrolizumab for Advanced Hepatocellular Carcinoma
We were delighted to talk to Jean-Luc Van Laethem (Hôpital Universitaire Erasme, Université Libre de Bruxelles, Brussels, Belgium) around pembrolizumab therapy in patients with previously untreated advanced hepatocellular carcinoma (Clinical Trial Identifier: NCT02702414). The abstract ‘Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study’ (ABSTRACT NUMBER: 297) was presented at […]
Jean-Luc Van Laethem, ASCO GI 2021: Results of the KEYNOTE-224 Study
We were delighted to talk to Jean-Luc Van Laethem (Hôpital Universitaire Erasme, Université Libre de Bruxelles, Brussels, Belgium) about the efficacy and safety findings of the KEYNOTE-224 study (Clinical Trial Identifier: NCT02702414). The abstract ‘Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study’ (ABSTRACT NUMBER: 297) was presented at the […]
Milind M. Javle, ASCO GI 2021 – Results from a Phase II Study of Infigratinib
We were delighted to talk to Milind Javle (University of Texas MD Anderson Cancer Center, Houston, TX, US) about the use of infigratinib for the treatment of patients with previously treated advanced cholangiocarcinoma (Clinical Trial Identifier: NCT02150967). The abstract ‘Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!